Accelerate biotechnology
News
Congress schedule
Resources

Batavia successfully uses innovative HIP-Vax to manufacture IAVI’s Lassa fever vaccine candidate for Phase I clinical trials

Leiden, The Netherlands, July 14, 2021 – Batavia Biosciences announces today that they have successfully produced vaccine material for a Phase I clinical trial of IAVI’s Lassa fever vaccine candidate, rVSV∆G-LASV-GPC. The vaccine candidate was manufactured using Batavia’s highly intensified vaccine manufacturing platform (HIP-Vax®). This platform uses the novel fixed-bed bioreactor, scale-X™, enabling the use…

Batavia to develop innovative clinical process for RocketVax’s second generation COVID-19 vaccine

Leiden, 6 July 2021 – Today, Batavia Biosciences announces their collaboration with RocketVax, a subsidiary of Swiss Rockets AG developing vaccines based on breakthrough genetic engineering. Under the agreement, Batavia will develop the clinical process and deliver clinical product of RocketVax’s vaccine candidate against the SARS-CoV-2 virus.  RocketVax is developing a promising second generation COVID-19…

Meet our newest team member: Alec

We would like to introduce you to our newest team member: kingfisher Alec! Alec is Batavia Biosciences’ official mascot. In this post, we would like to explain how we found Alec. Why a kingfisher First, as you know, Batavia Biosciences is headquartered in the Netherlands. The motto of the founder of the Dutch monarchy, Prince…

Batavia Biosciences and Valneva Collaborate to Accelerate Development of Low-cost Inactivated Polio Vaccine

Saint-Herblain, France, and Leiden, Netherlands, June 15, 2020 – Batavia Biosciences (“Batavia”) and Valneva Sweden AB, the Swedish subsidiary of Valneva SE (“Valneva”) today announced that they have entered into a collaboration agreement to accelerate market-access of a low-cost inactivated polio vaccine (IPV). This work is supported under GPEI.[1] In 2019, Batavia received a grant…

Batavia successfully navigating coronavirus pandemic

As the COVID-19 pandemic continues, we would like to update you on our business status. As a company at the forefront of epidemic preparedness, staying operational is critical as it means we can continue the valuable work we do with our clients and partners to develop treatments and cures for vaccine preventable diseases. We put…

The Wistar Institute and Batavia Biosciences Launch Collaboration to Manufacture and Distribute Wistar’s Rubella Vaccine Globally

The Bill & Melinda Gates Foundation supports international collaboration to expand global access to life-saving vaccines PHILADELPHIA — (April 29, 2020) — The Wistar Institute and Batavia Biosciences announce the launch of a strategic collaboration aimed to streamline the clinical grade manufacture and global distribution of Wistar’s rubella vaccine seed stock commonly known as RA…

Collaboration with IAVI on VSV-vector Based Epidemic Preparedness Vaccines

Mutual expertise drives innovations to address supply issues for vaccines for outbreak pathogens NEW YORK — MARCH 5, 2020 — IAVI, a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges, and Batavia Biosciences, a contract development and manufacturing organization focused on delivering sustainable manufacturing solutions in the field of infectious disease…

We are celebrating our 10-year anniversary!

Ten years ago, Christopher Yallop and Menzo Havenga incorporated Batavia Biosciences at the chamber of commerce in the Netherlands. The company started operations on January 1, 2010 at that time with 7 employees (our “magnificent seven”). Today, we are a 100 people strong with operations in the US, Asia, and the Netherlands and we are…

COVID-19 Message

Please read the message from our executive management regarding the precautionary measures at Batavia Biosciences.

 

Read the message here